Calanolide B is a natural product isolated from the plant Calophyllum lanigerum. It exhibits promising anti-HIV activity and has been shown to inhibit the replication of HIV-1 in cell culture. The compound is a potent inhibitor of the HIV-1 reverse transcriptase enzyme, which is crucial for the virus's life cycle. Calanolide B's potential as an anti-HIV drug has attracted significant research interest. Its unique chemical structure and biological activity have motivated scientists to investigate its synthesis and explore its therapeutic applications. Studies have been conducted to understand the compound's mechanism of action and to develop analogs with improved potency and pharmacokinetic properties. Calanolide B and its derivatives continue to be investigated as potential lead compounds for the development of new anti-HIV therapies.'
calanolide B: structure given in first source; one of a novel class of HIV-inhibiting coumarins from the tropical rainforest tree, Calophyllum lanigerum
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Calophyllum | genus | A plant genus of the family CLUSIACEAE. Members contain costatolide, calanolides and 4-phenylfuranocoumarins (FUROCOUMARINS).[MeSH] | Calophyllaceae | [no description available] |
Calophyllum lanigerum | species | [no description available] | Calophyllaceae | [no description available] |
ID Source | ID |
---|---|
PubMed CID | 65008 |
CHEMBL ID | 7121 |
SCHEMBL ID | 212038 |
MeSH ID | M0204436 |
Synonym |
---|
calanolide b |
(+)-calanolide b (synthetic) |
2',3'-h]chromene-2-one |
nsc-675450 |
(+)-(12r)-hydroxy-6,11s)-dimethyl-4-propyl-6,10,11,12-tetrahydrodipyrano[2,3-f |
142632-33-5 |
2h,6h,10h-benzo[1,2-b:3,4-b':5,6-b'']tripyran-2-one,11,12-dihydro-12-hydroxy-6,6,10,11-tetramethyl-4-propyl-,(10r,11s,12r)- |
(+)-calanolide b |
nsc675450 |
CHEMBL7121 |
2h,6h,10h-benzo(1,2-b:3,4-b':5,6-b'')tripyran-2-one, 11,12-dihydro-12-hydroxy-6,6,10,11-tetramethyl-4-propyl-, (10r,11s,12r)- |
2h,6h,10h-benzo(1,2-b:3,4-b':5,6-b'')tripyran-2-one, 11,12-dihydro-12-hydroxy-6,6,10,11-tetramethyl-4-propyl-, (10r-(10alpha,11beta,12beta))- |
nsc 675450 |
ccris 9389 |
bdbm50428437 |
SCHEMBL212038 |
DTXSID80162110 |
(16r,17s,18r)-18-hydroxy-10,10,16,17-tetramethyl-6-propyl-3,9,15-trioxatetracyclo[12.4.0.02,7.08,13]octadeca-1(14),2(7),5,8(13),11-pentaen-4-one |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Carbonic anhydrase 12 | Homo sapiens (human) | Ki | 0.8100 | 0.0002 | 1.1043 | 9.9000 | AID729559 |
Carbonic anhydrase 1 | Homo sapiens (human) | Ki | 9.3100 | 0.0000 | 1.3726 | 10.0000 | AID729563 |
Carbonic anhydrase 2 | Homo sapiens (human) | Ki | 50.7000 | 0.0000 | 0.7236 | 9.9200 | AID729562 |
Carbonic anhydrase 7 | Homo sapiens (human) | Ki | 8.8700 | 0.0002 | 1.3737 | 9.9000 | AID729561 |
Carbonic anhydrase 9 | Homo sapiens (human) | Ki | 0.8300 | 0.0001 | 0.7874 | 9.9000 | AID729560 |
Carbonic anhydrase 13 | Homo sapiens (human) | Ki | 21.0000 | 0.0003 | 1.2309 | 9.8000 | AID729558 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID729562 | Inhibition of human carbonic anhydrase 2 preincubated for 6 hrs by CO2 hydration stopped-flow assay | 2013 | Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6 | Natural product coumarins that inhibit human carbonic anhydrases. |
AID729561 | Inhibition of human carbonic anhydrase 7 preincubated for 6 hrs by CO2 hydration stopped-flow assay | 2013 | Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6 | Natural product coumarins that inhibit human carbonic anhydrases. |
AID729563 | Inhibition of human carbonic anhydrase 1 preincubated for 6 hrs by CO2 hydration stopped-flow assay | 2013 | Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6 | Natural product coumarins that inhibit human carbonic anhydrases. |
AID46612 | Maximum protection of human T-lymphoblastic cells(CEM-SS) from cytopathic effects of HIV-1 by the compound | 1992 | Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15 | The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum. |
AID235765 | Apparent in vitro therapeutic induces(TI) of the compound | 1992 | Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15 | The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum. |
AID729558 | Inhibition of human carbonic anhydrase 13 preincubated for 6 hrs by CO2 hydration stopped-flow assay | 2013 | Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6 | Natural product coumarins that inhibit human carbonic anhydrases. |
AID46263 | Potency to inhibit HIV-1 induced cytopathic effects in human T-lymphoblastic cells(CEM-SS) and essentially halted HIV-1 replication. | 1992 | Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15 | The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum. |
AID729560 | Inhibition of human carbonic anhydrase 9 preincubated for 6 hrs by CO2 hydration stopped-flow assay | 2013 | Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6 | Natural product coumarins that inhibit human carbonic anhydrases. |
AID46444 | Concentration inhibiting HIV-1 induced cytopathic effects in human T-lymphoblastic cells(CEM-SS) and essentially halted HIV-1 replication. | 1992 | Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15 | The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum. |
AID729559 | Inhibition of human carbonic anhydrase 12 preincubated for 6 hrs by CO2 hydration stopped-flow assay | 2013 | Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6 | Natural product coumarins that inhibit human carbonic anhydrases. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (60.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.53) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |